The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Somaxon Pharmaceuticals has submitted a NDA for Silenor for the treatment of insomnia. The active ingredient is doxepin, which has been available for years.The effect of the drug can be expected to be very modest, side effects unfavorable when compared to Ambien or Lunesta, and with both significant...
What is the best way to market pharmaceutical and other medical products to physicians? There is certainly bias among some physicians against the pharmaceutical industry. It is felt by many that industry sponsored research studies are invalid and will always show the products in a favorable light. On...
I feel that this drug could make a major impact on treatment of depression due to it unique mechanism of action eg increasing all three neurotransmitters without the old side effects of MAOI.
Xenoport's trial for XP13512 in restless legs syndrome (RLS) shows strongly positive 9 month data in second phase 3 trial, should be a major win in the marketplace. RLS represent a major unmet need, for drugs with sustained efficacy and high tolerability.
the use of Vertex polyaxial screws is only a minor part of the spinal implant protfolio at Medtronic (MDT:NYSE). This should not affect the bottom line to any significant extent.
This is a very significant event for Ceregene. Previous studies, with drug treatment, on treatment for parkinsons have shown that the placebo effect only lasts for three months. The symptoms of Parkinson's increase 5-10% per year( as part of the natural progression of the disorder). ...
UCB has filed new drug application for regulatory approval for lacosamide through FDA and European Medicines Agency. Primary indication would be the treatment of partial onset seizures (epilepsy)
I believe this will only enhance our arenal for the treament of schizophrenia and bipolar disorder in that the long acting version will enhance compliance and maintain better levels of the drug in patients.